Pieris Reports AstraZeneca Discontinuation Of Phase 2a Trial Of Elarekibep (PRS-060/AZD1402) Due To New Non-Clinical Safety Findings From 13-Week Toxicology Study
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca has discontinued the Phase 2a trial of Elarekibep (PRS-060/AZD1402) due to new non-clinical safety findings from a 13-week toxicology study. Pieris will review the implications of the data and AstraZeneca's decision before providing further updates.
June 21, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca discontinues Phase 2a trial of Elarekibep due to safety concerns, potentially impacting the company's drug pipeline.
AstraZeneca's decision to discontinue the Phase 2a trial of Elarekibep may negatively impact the company's drug pipeline and future revenue potential. The safety concerns could also affect investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Pieris will review the implications of AstraZeneca's decision to discontinue the Phase 2a trial of Elarekibep, potentially affecting the company's collaboration and future projects.
Pieris is directly involved in the development of Elarekibep, and AstraZeneca's decision to discontinue the trial may negatively impact their collaboration and future projects. This could affect Pieris' stock price in the short term as investors reassess the company's prospects.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100